Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.8352W HIGH $6.88
Volume
7.04 M
Value Traded
9.14 M
Short % Float
30.5%
+14.79%Week
-54.89%1 Month
-57.79%3 Month
-80.98%6 Month
-51.29%5 Year
-75.65%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
177.10 M
EPS (TTM)
-0.41
P/E Ratio
-
Ent. Value
-2.78 M
Total Shares
180.17 M
Float Shares
136.56 M
Insiders
24.17%
Institutions
73.24%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
CMPX Catalyst Timeline
Dated clinical, regulatory and corporate events for Compass Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Compass Therapeutics, Inc.
320Total events
14Upcoming
60Tier-1 (high impact)
2020 to 2028Coverage
Upcoming catalysts 2
Event history 50
▼FDA Feedback ReceivedCTX-009FiledFDA Meeting
FDA feedback recommends survival trial before tovecimig BLA submission
previously treated, advanced biliary tract cancer (BTC)source ↗
●Enrollment UpdateCTX-8371Trial
Cohort expansions for CTX-8371 actively enrolling
triple-negative breast cancer, non-small cell lung cancer, Hodgkin lymphomasource ↗
▲First Patient DosedCTX-10726Trial
First patients dosed in Phase 1 study of CTX-10726
solid tumorssource ↗
●Trial InitiationCTX-009FiledTrial
IST of tovecimig plus FOLFIRI in colorectal cancer initiated
colorectal cancersource ↗
●Enrollment UpdateCTX-009FiledTrial
IST of tovecimig with gemcitabine, cisplatin, durvalumab ongoing with expansion to additional sites expected
biliary tract cancersource ↗
◆FDA Feedback ReceivedCTX-009FiledFDA Meeting
FDA feedback expected on COMPANION-002 data for tovecimig in BTC
biliary tract cancersource ↗
●Trial InitiationCTX-471Trial
Phase 2 study of CTX-471 to be initiated in Q3 2026
tumors expressing NCAM (CD56)source ↗
◆Oral PresentationPresentation
Goldman Sachs 47th Annual Global Healthcare Conference presentation
●Oral PresentationCTX-8371Presentation
Phase 1 dose-escalation data presented at ASCO 2026
solid tumorssource ↗
◆Poster PresentationCTX-8371Presentation
Poster presentation of Phase 1 dose escalation data for CTX-8371 at ASCO 2026
advanced malignancies (post-checkpoint inhibitor setting)source ↗
◆Oral PresentationPresentation
H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
◆Oral PresentationCTX-009FiledPresentation
Webcast to review topline secondary endpoints from COMPANION-002 study of tovecimig in BTC
advanced biliary tract cancersource ↗
▼Full ResultsCTX-009FiledClinical Data
COMPANION-002 tovecimig overall survival data disclosed
cancersource ↗
▲Topline ReadoutCTX-009FiledClinical Data
Key secondary endpoint PFS met: median 4.7 vs 2.6 months (HR=0.44, p<0.0001)
biliary tract cancersource ↗
▼Secondary Endpoint DataCTX-009FiledClinical Data
OS secondary endpoint did not meet statistical significance due to crossover
biliary tract cancersource ↗
▲Primary Endpoint MetCTX-009FiledClinical Data
Final analysis of COMPANION-002 shows improved ORR and p-value
biliary tract cancersource ↗
▲Topline ReadoutCTX-009FiledClinical Data
Tovecimig topline data announced: PFS and OS results
biliary tract cancersource ↗
▲Orphan Drug DesignationCTX-009FiledDesignation
Tovecimig received Orphan Drug Designation
biliary tract cancersource ↗
◆Oral PresentationCTX-8371Presentation
Initial data from CTX-8371 expansion cohorts and dose-escalation to be presented at major medical conference in Q2 2026
TNBC, NSCLCsource ↗
◆Oral PresentationCTX-009FiledPresentation
Tovecimig Phase 2 CRC data at ASCO GI 2026
advanced metastatic colorectal cancersource ↗
◆Topline ReadoutCTX-009FiledClinical Data
Secondary endpoint analyses (OS, PFS) expected in Q1 2026
biliary tract cancersource ↗
●Enrollment MilestoneCTX-009FiledTrial
Prespecified event threshold of 80% OS events reached in COMPANION-002
biliary tract cancersource ↗
▲First Patient DosedCTX-8371Trial
Expansion cohort for TNBC open and enrolling
triple-negative breast cancersource ↗
▲First Patient DosedCTX-10726Trial
Phase 1 study of CTX-10726 open for enrollment in Q1
solid tumorssource ↗
◆Poster PresentationCTX-10726Presentation
Poster presentation of preclinical data on CTX-10726 at SITC 2025
cancersource ↗
Past FDA Catalysts and PDUFA Decisions
How CMPX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-06-30 | CTX-8371 | Phase 1 data presentation | Phase 1 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C50 / 100
Pipeline Score
$293M
Pipeline Value
Fair Value
Valuation Signal
5
Drugs Scored
1.7x
rNPV / MCap
Top 17%
Micro Cap(rank 113 of 658)
Percentile Rank
Compass Therapeutics, Inc. carries a moderate pipeline score (50/100), with $1.2B risk-adjusted pipeline value, led by CTX-471 in Neuroendocrine Neoplasm (Phase 2).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| CTX-471 Small moleculeNCT07684170 | Neuroendocrine Neoplasm | Phase 2 | NOT YET_RECRUITING | 58 | Sep 1, 2029 |
Clinical Trial Results
Readouts, endpoints and source filings for every CMPX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| CTX-8371 | advanced malignancies | Phase 1 | 2026-05-22 | deep, confirmed, and durable responses observed in patients with NSCLC, TNBC and HLRead More | Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual MeetingRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Lerner NeilOfficer (Chief Accounting Officer) | Buy | 20,000 420,000 held | $0.92 | 10/01/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in CMPX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 1.8 % (-60 %) | 39.40 M | 17.99 M | 7.15% ( 1.20 M) |
CMPX Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2028-01-21 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How CMPX ranks across every disease it competes in
Competitive Position is a premium feature
See how CMPX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialCMPX News
CMPX▼ -31.9%on this news
Compass Therapeutics Provides Regulatory Update on Tovecimig in Biliary Tract Cancer Following FDA Feedback
Compass Therapeutics announced that the FDA has recommended conducting a trial to demonstrate a survival benefit for tovecimig before submitting a Biologics License Application for its use in biliary tract cancer. Despite this, Compass is confident in the drug's efficacy based on positive results from the Phase 2/3 COMPANION-002 study, which showed significant improvements in objective response rate and progression-free survival. The company plans to engage further with the FDA as it prepares for the BLA submission.
Read more →CMPX▲ +5.3%on this news· ran to +16% by day 3
Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update
Compass Therapeutics reported its second quarter 2026 financial results, highlighting positive developments in its clinical pipeline. The company anticipates FDA feedback on tovecimig data, which is also set for presentation at the ESMO Congress. Additionally, CTX-8371 is actively enrolling patients in Phase 1 cohort expansions, while other studies are progressing as planned.
Read more →CMPXCompass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026
Compass Therapeutics announced that its abstract on tovecimig has been accepted for an oral presentation at the ESMO Congress 2026. The presentation will discuss the results of the Phase 2/3 COMPANION-002 clinical trial, which evaluates tovecimig in combination with paclitaxel for advanced biliary tract cancer. The congress is scheduled for October 23-27, 2026, in Madrid, Spain.
Read more →CMPX▲ +6.2%on this news
Compass Therapeutics to Participate in Upcoming June Investor Events
Compass Therapeutics, Inc. will participate in two major investor events in June 2026, including the Jefferies Global Healthcare Conference and the Goldman Sachs 47th Annual Global Healthcare Conference. The company aims to engage with investors and provide insights into its oncology-focused therapeutic developments. Presentations will be available for replay on their events page.
Read more →CMPX▲ +7.3%on this news· ran to +25% by day 3shared move
Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual Meeting
Compass Therapeutics announced a poster presentation of Phase 1 clinical data for CTX-8371 at the 2026 ASCO Annual Meeting. The data highlights promising responses in patients with advanced malignancies treated after checkpoint inhibitors. The company is expanding cohorts for further study and plans to report additional data later in 2026.
Read more →CMPXCompass Therapeutics to Participate in Upcoming May Investor Events
Compass Therapeutics, a clinical-stage biopharmaceutical company, announced its participation in two upcoming investor events in May 2026. The events include the H.C. Wainwright 4th Annual BioConnect Investor Conference and the 2026 Stifel Virtual Targeted Oncology Forum. Management will also be available for one-on-one meetings with interested investors.
Read more →CMPXCompass Therapeutics Reports 2026 First Quarter Financial Results and Provides Corporate Update
Compass Therapeutics reported its first quarter 2026 financial results, highlighting positive data from its Phase 2/3 study of tovecimig for biliary tract cancer. The company plans to submit a Biologics License Application (BLA) later this year. Additionally, it has ongoing studies for other bispecific antibodies, CTX-8371 and CTX-10726, with promising initial results. Despite a net loss, the company maintains a strong cash position.
Read more →CMPX▼ -64.4%on this news
Tovecimig Demonstrates Statistically Significant Benefit in COMPANION-002 Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer
Compass Therapeutics announced that tovecimig, in combination with paclitaxel, significantly improved progression-free survival in patients with biliary tract cancer compared to paclitaxel alone. The study met its key secondary endpoint with a median PFS of 4.7 months. However, overall survival results were complicated by a high crossover rate from the control group. The company plans to engage with the FDA for a Biologics License Application submission.
Read more →CMPXCompass Therapeutics to Announce Topline Secondary Endpoints from the Phase 2/3 COMPANION-002 Study of Tovecimig in Patients with Biliary Tract Cancer
Compass Therapeutics announced it will host a webcast on April 27, 2026, to present topline secondary endpoints from its Phase 2/3 COMPANION-002 study. This clinical study evaluates tovecimig, a bispecific antibody targeting DLL4 and VEGF-A, in combination with paclitaxel for patients with advanced biliary tract cancer. The event highlights the company's commitment to clinical development and investor communication.
Read more →CMPXCompass Health Invites Community to “Camp Out” for Youth Behavioral Health
Compass Health is hosting The Great Compass Health Camp Out on April 17, 2026, to fundraise for its child and youth programs. The event, open to guests 21 and older, will include nostalgic games, camp activities, and speakers sharing impactful stories. This marks the return of Compass Health's annual fundraiser and aims to address the growing behavioral health needs among youth in Northwest Washington. Community members are encouraged to attend and support the organization during these challenging times for behavioral health providers.
Read more →CMPXCompass Therapeutics Reports 2025 Financial Results and Provides Corporate Update
Compass Therapeutics reported its 2025 financial results, highlighting significant progress in its clinical trials, particularly with tovecimig in biliary tract cancer. The company has a strong cash position of $209 million, allowing operations into 2028. Upcoming data releases and trial expansions are anticipated to enhance its pipeline and market position.
Read more →CMPXCompass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - January 5, 2026
Compass Therapeutics has announced the grant of stock options to its new Chief Commercial Officer and Chief Medical Officer as part of its 2025 Inducement Plan. Each executive will receive options to purchase 1,000,000 shares at an exercise price of $5.17, vesting over four years. This move is in accordance with Nasdaq Listing Rule 5635(c)(4) and aims to enhance the company's leadership.
Read more →CMPXCompass Therapeutics Provides Corporate Update
Compass Therapeutics provided a corporate update highlighting progress in its clinical pipeline, including advancements in its bispecific antibodies. They expect key analyses of the tovecimig study for biliary tract cancer in late Q1 2026, which may influence future treatments. The company has confirmed durable responses in patients treated with CTX-8371 for various cancers and opened enrollment for cohort expansions. Additionally, with $209 million in cash reserves, Compass is well-positioned to advance its innovative oncology therapies.
Read more →CMPXCompass Therapeutics Announces Key Leadership Appointments
Compass Therapeutics has appointed Arjun Prasad as Chief Commercial Officer and Cynthia Sirard as Chief Medical Officer, effective January 1, 2026. Both leaders bring extensive experience in oncology, with Prasad's background in product launches and Sirard's expertise in clinical development. Their appointments are expected to strengthen Compass's ability to advance its therapeutic pipeline.
Read more →CMPX▼ -5.3%on this news
Compass Therapeutics to Participate in the J.P. Morgan 2026 Healthcare Conference
Compass Therapeutics, a clinical-stage oncology biopharmaceutical company, will present at the J.P. Morgan 2026 Healthcare Conference on January 14, 2026. The company is focused on developing antibody-based therapeutics and will also host investor meetings prior to the conference. Their scientific efforts are centered on targeting critical biological pathways for effective anti-tumor responses.
Read more →CMPXCompass Therapeutics to Participate in Upcoming December Investor Events
Compass Therapeutics, Inc. (Nasdaq: CMPX), an oncology-focused biopharmaceutical company, announced its participation in upcoming investor events in December. The events include the Piper Sandler 37th Annual Healthcare Conference in New York on December 2 and the 8th Annual Evercore Healthcare Conference in Coral Gables on December 4. The company will hold one-on-one meetings with interested investors and will archive the presentations for 90 days. This participation underscores Compass Therapeutics' commitment to engaging with the investment community.
Read more →CMPXCompass Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Compass Therapeutics reported its third quarter 2025 financial results, highlighting significant progress in its clinical pipeline, particularly with tovecimig for advanced BTC. The company anticipates reporting overall survival and progression-free survival data in late Q1 2026. Additionally, CTX-8371 has shown promising responses in patients, and the company secured $138 million in financing to support its initiatives.
Read more →CMPXCompass Therapeutics Presents Preclinical Data on CTX-10726, a Differentiated PD-1 x VEGF-A Bispecific Antibody, at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting
Compass Therapeutics has announced a poster presentation for CTX-10726 at the SITC Annual Meeting. This bispecific antibody targets PD-1 and VEGF-A, aiming to improve treatment outcomes for cancer patients. The presentation will showcase preclinical data supporting its efficacy in enhancing anti-tumor responses. CTX-10726 is currently undergoing IND-enabling studies.
Read more →CMPXCompass Therapeutics to Participate in Upcoming November Investor Events
Compass Therapeutics, a clinical-stage biopharmaceutical company, has announced its participation in several investor events throughout November 2025. These events include the Guggenheim Healthcare Innovation Conference, Stifel Healthcare Conference, and Jefferies Global Healthcare Conference, providing a platform for the company to present its advancements in oncology-focused therapeutics. Presentations will be archived for 90 days for further accessibility.
Read more →About Compass Therapeutics, Inc.
Headquarters80 GUEST STREET, BOSTON, MA, 02135
BIOPHARMAWATCH ELITE PLUS
Trade the next CMPX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime